{
  "id": "61fbc1acc9dfcb9c0900000d",
  "type": "list",
  "question": "Which drugs are included in the Lonsurf combination pill?",
  "ideal_answer": "Lonsurf is an oral fixed dose combination of trifluridine and tipiracil that is used for cancer treatment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
    "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
    "http://www.ncbi.nlm.nih.gov/pubmed/31002008",
    "http://www.ncbi.nlm.nih.gov/pubmed/33468799",
    "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
    "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
    "http://www.ncbi.nlm.nih.gov/pubmed/32801768",
    "http://www.ncbi.nlm.nih.gov/pubmed/34207352",
    "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
    "http://www.ncbi.nlm.nih.gov/pubmed/33294265",
    "http://www.ncbi.nlm.nih.gov/pubmed/34034550",
    "http://www.ncbi.nlm.nih.gov/pubmed/31489588",
    "http://www.ncbi.nlm.nih.gov/pubmed/27568360",
    "http://www.ncbi.nlm.nih.gov/pubmed/32891715"
  ],
  "snippets": [
    {
      "text": "TAGS trial revealed the efficacy and safety of trifluridine/tipiracil(Lonsurf\u00ae)treatment in patients with metastatic gastric cancer following gastrectomy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33468799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "What is already known TAS 102 (Lonsurf) is an oral fixed dose combination of trifluridine (FTD) and tipiracil (TPI) indicated as salvage-line treatment in patients with therapy refractory metastatic colorectal cancer (mCRC). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31002008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (Lonsurf\u00ae) is a fixed-dose combination tablet comprising trifluridine, an antineoplastic nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil or TAS-102 (Taiho Oncology, Lonsurf\u00ae, Princeton, NJ, USA) is a combination tablet of trifluridine, a thymidine-based nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor, in a 1:0.5 molar ratio.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32801768",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102/Lonsurf is a new oral anti-tumor drug consisting of trifluridine and tipiracil in a 1:0.5 molar ratio. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294265",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102 (Lonsurf) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs: trifluridine (a nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil or TAS-102 (Taiho Oncology, Lonsurf\u00ae, Princeton, NJ, USA) is a combination tablet of trifluridine, a thymidine-based nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor, in a 1:0.5 molar ratio. This drug was first a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32801768",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (Lonsurf\u00ae) is a fixed-dose combination tablet comprising trifluridine, an antineoplastic nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor. Tr",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "S-102 (Lonsurf) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs: trifluridine (a nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor). This ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " two Asian efficacy trials. What is already known TAS 102 (Lonsurf) is an oral fixed dose combination of trifluridine (FTD) and tipiracil (TPI) indicated as salvage-line treatment in patients with therapy refractory metastatic co",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31002008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil or TAS-102 (Taiho Oncology, Lonsurf\u00ae, Princeton, NJ, USA) is a combination tablet of trifluridine, a thymidine-based nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor, in a 1:0.5 molar ratio. This dr",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32801768",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In May 2014, tablets containing both trifluridine and tipiracil hydrochloride (Lonsurf\u00ae tablets) were launched in Japan ahead of other countries, for the treatment of advanced/relapsed unresectable colorectal cancer. The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102/Lonsurf is a new oral anti-tumor drug consisting of trifluridine and tipiracil in a 1:0.5 molar ratio",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294265",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (Lonsurf(\u00ae)) is a novel, orally active, antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor. Triflur",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27568360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (FTD/TPI; marketed as Lonsurf\u00ae) has shown clinically relevant activity after fluoropyrimidine failure in colorectal cancer and may thus be of increased efficacy compared with current standard capecitabine chemoradiation. H",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32891715",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "erapy. These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102/Lonsurf is a new oral anti-tumor drug consisting of trifluridine and tipiracil in a 1:0",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294265",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In May 2014, tablets containing both trifluridine and tipiracil hydrochloride (Lonsurf\u00ae tablets) were launched in Japan ahead of other countries, for the treatment of advanced/relapsed unresectable colorectal cancer",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lonsurf (trifluridine/tipiracil): Assessing the impact of dose related toxicities and progression free survival in (refractory) metastatic colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34034550",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standar",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In May 2014, tablets containing both trifluridine and tipiracil hydrochloride (Lonsurf\u00ae tablets) were launched in Japan ahead of other countries, for the treatment of advanced/relapsed unresectable colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102/Lonsurf is a new oral anti-tumor drug consisting of trifluridine and tipiracil in a 1:0.5 molar ratio.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294265",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (FTD/TPI; marketed as Lonsurf\u00ae) has shown clinically relevant activity after fluoropyrimidine failure in colorectal cancer and may thus be of increased efficacy compared with current standard capecitabine chemoradiation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32891715",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the RECOURSE trial which lead to its accreditation, Lonsurf (trifluridine/tipiracil) was shown to extend progression free survival (PFS) by 1.8\u2009months in metastatic colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34034550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAGS trial revealed the efficacy and safety of trifluridine/tipiracil(Lonsurf\u00ae)treatment in patients with metastatic gastric cancer following gastrectomy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33468799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the UK, Trifluridine-tipiracil (Lonsurf) is used to treat metastatic colorectal cancer in the third-line setting, after prior exposure to fluoropyrimidine-based regimes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34207352",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evolocumab (Repatha) for patients with hypercholesterolemia whose condition has not been controlled by statins and other therapies; trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer; and blood coagulation factor VIII (Nuwiq) for adults and children with hemophilia A.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "trifluridine, tipiracil"
}